Dr. Chen Wang 王忱
Chief Physician
Department of Breast Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for malignant tumors, with a focus on chemotherapy, endocrine therapy, molecular targeted therapy, and immunotherapy for breast cancer.
Dr. Wang earned a bachelor's degree from Tianjin Medical University in 1999, a master's in oncology in 2002, and a doctorate in 2008 under Academician Hao Xishan. Dr. Wang completed postdoctoral research at the H. Lee Moffitt Cancer Center (2010–2013). A member of the American Association for Cancer Research (AACR), Dr. Wang has participated in National Natural Science Foundation projects and clinical trials, publishing nearly 20 papers.
Professional roles
- Member, Chinese Medical Association
- Youth Member, Breast Oncology Group, Oncology Branch, Chinese Medical Association
- Chair, Breast Disease Professional Committee, Tianjin Medical Health Association
- Member, Multidisciplinary Diagnosis and Treatment Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Chen). Papers usually list the name as Chen Wang or Wang C.
Selected publications
31 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transfus Apher Sci, 2026 (first author): Identification strategy for patients with ABO blood typing difficulties caused by IgM autoantibodies. PubMed 41534470
- Discov Oncol, 2025 (senior author): Glutamate promotes triple-negative breast cancer development through IRE1α/XBP1-mediated macrophage polarization: mechanism insights and therapy. PubMed 40471465
- Cancer Res, 2021 (first author): Long Noncoding RNA CTD-2245E15.3 Promotes Anabolic Enzymes ACC1 and PC to Support Non-Small Cell Lung Cancer Growth. PubMed 33941610
- Mol Ther Nucleic Acids, 2020 (senior author): LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer. PubMed 33251049
- Int J Clin Exp Med, 2015 (first author): miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. PubMed 26629059
- J Nutr Biochem, 2015 (first author): EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. PubMed 25997867
- Mol Med Rep, 2014 (senior author): Role and mechanisms of microRNA‑503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. PubMed 25269574
- Mol Cell Biochem, 2012 (senior author): Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation. PubMed 22147199
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion